$1.87
8.33%
Nasdaq, Oct 10, 10:05 pm CET
ISIN
US22053A1079
Symbol
QNCX

Cortexyme, Inc. Stock price

$1.87
+0.26 16.15% 1M
+0.86 85.15% 6M
+0.00 0.00% YTD
+1.15 159.72% 1Y
+0.85 83.33% 3Y
-49.10 96.33% 5Y
-15.13 89.00% 10Y
-15.13 89.00% 20Y
Nasdaq, Closing price Fri, Oct 10 2025
-0.17 8.33%
ISIN
US22053A1079
Symbol
QNCX
Industry

Key metrics

Basic
Market capitalization
$100.4m
Enterprise Value
$82.7m
Net debt
positive
Cash
$34.7m
Shares outstanding
53.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.6
Financial Health
Equity Ratio
26.3%
Return on Equity
-188.5%
ROCE
-39.0%
ROIC
-
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-42.6m | -
EBIT
$-42.7m | $-47.4m
Net Income
$-49.0m | $-59.0m
Free Cash Flow
$-36.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-12.3% | -
EBIT
-11.6% | -18.1%
Net Income
7.7% | -3.8%
Free Cash Flow
-29.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-0.7
Short interest
1.9%
Employees
36
Rev per Employee
$0.0
Show more

Is Cortexyme, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

Cortexyme, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Cortexyme, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Cortexyme, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Cortexyme, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
37% 37%
-
- Research and Development Expense 30 30
108% 108%
-
-43 -43
12% 12%
-
- Depreciation and Amortization 0.17 0.17
56% 56%
-
EBIT (Operating Income) EBIT -43 -43
12% 12%
-
Net Profit -49 -49
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cortexyme, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cortexyme, Inc. Stock News

Neutral
Business Wire
3 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of patient-reported walking capacity in children with Ataxia-Telangiectasia (A-T) at the 54th Child Neurology Society (...
Neutral
Seeking Alpha
10 days ago
Quince Therapeutics, Inc. (NASDAQ:QNCX ) Analyst/Investor Day October 2, 2025 10:00 AM EDT Company Participants Dirk Thye - CEO, Chief Medical Officer & Director Giovanni Mambrini - Chief Technology Officer Caralee Schaefer Pamela Williamson - Head of Regulatory Affairs Charles Ryan - President Brendan Hannah - Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Acco...
Neutral
Business Wire
17 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the publication of an advanced population pharmacokinetic (PK) modeling study of pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adul...
More Cortexyme, Inc. News

Company Profile

Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Dirk Thye
Employees 36
Founded 2012
Website quincetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today